Stryker investe USD 400 milioni in azioni privilegiate CMR Surgical per Versius
- Stryker investirà circa USD 400 milioni (GBP 300 milioni) in CMR Surgical tramite preferred equity, subordinato alle consuete condizioni di closing.
- L’operazione concede un’opzione esclusiva per acquisire in futuro il 100% del capitale di CMR Surgical, alle condizioni dell’accordo.
- Intesa affiancata da un mandato commerciale esclusivo negli Stati Uniti per il portafoglio Versius; CMR mantiene sviluppo e vendite fuori dagli USA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stryker Corporation published the original content used to generate this news brief via GlobeNewswire on October 12, 2026, and is solely responsible for the information contained therein.